Skip to main content

Table 2 Overall change from baseline in MIDAS total score, headache days, headache pain, and number of treated attacks for patients who completed all 4 quarters of treatment

From: Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

  Lasmiditan 100 mg (n = 974)Lasmiditan 200 mg (n = 1063)
Change from BL*Change from BL*
LS mean% change in LS meanLS mean% change in LS mean
MIDAS Total ScoreBL, meana29.428.9
Month 3−7.7−26.3− 7.0−24.3
Month 6−9.8− 33.5− 9.2− 31.9
Month 9− 11.0− 37.6− 10.1− 34.9
Month 12−12.5− 42.6− 12.2− 42.2
Headache Days, past 3 monthsb, cBL, mean15.515.5
Month 3−3.5− 22.6− 3.9− 24.8
Month 6−4.5−28.7− 4.1− 26.1
Month 9−5.2− 33.7− 5.7− 36.7
Month 12−5.7− 36.8−6.0−38.8
Average headache pain intensityb, dBL, mean7.47.3
Month 3−0.4−5.4− 0.4− 5.7
Month 6−0.7−9.1− 0.7−9.0
Month 9−0.8−10.4−0.9−11.9
Month 12−1.1− 15.1− 1.2− 16.6
Number of treated attacks, past 3 monthse Lasmiditan 100 mgLasmiditan 200 mg
NMeanNMean
Month 33266.03206.0
Q23125.02964.9
Q33034.42984.3
Q43363.7**3313.4**
  1. Abbreviations: BL baseline; LS mean = least squares mean
  2. aBaseline n = 972 for lasmiditan 100 mg. bNot included in MIDAS total score. c“On how many days in the past 3 months did you have a headache? (If a headache lasted more than 1 day, count each day)” dScale 1–10. eData shown for patients who completed all 4 quarters. *All changes from baseline significant at p < 0.001. **p-values from paired t-tests vs 1st quarter
\